Drew Pardoll
#43,702
Most Influential Person Now
Researcher
Drew Pardoll's AcademicInfluence.com Rankings
Drew Pardollbiology Degrees
Biology
#1475
World Rank
#2469
Historical Rank
Immunology
#52
World Rank
#57
Historical Rank
Drew Pardollphilosophy Degrees
Philosophy
#1874
World Rank
#3310
Historical Rank
Logic
#342
World Rank
#676
Historical Rank
Download Badge
Biology Philosophy
Why Is Drew Pardoll Influential?
(Suggest an Edit or Addition)According to Wikipedia, Andrew Mark Pardoll is Director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy and Abeloff Professor of Oncology, Medicine, Pathology and Molecular Biology and Genetics at Johns Hopkins University, School of Medicine. He is also Director of the Cancer Immunology Program at the Sidney Kimmel Comprehensive Cancer Center.
Drew Pardoll's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. (2012) (10640)
- The blockade of immune checkpoints in cancer immunotherapy (2012) (10267)
- Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. (2012) (6726)
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade (2017) (4313)
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. (2015) (3718)
- STATs in cancer inflammation and immunity: a leading role for STAT3 (2009) (3668)
- Immune checkpoint blockade: a common denominator approach to cancer therapy. (2015) (3000)
- Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. (2010) (2647)
- Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. (2014) (2043)
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy (2014) (1984)
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape (2012) (1936)
- Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy (2016) (1848)
- Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment (2007) (1704)
- The Central Role of CD4+ T Cells in the Antitumor Immune Response (1998) (1411)
- A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses (2009) (1394)
- Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. (1994) (1261)
- Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer (2018) (1203)
- Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. (2012) (1203)
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. (2012) (1192)
- Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis (2002) (1186)
- Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells (2004) (1141)
- Role of LAG-3 in regulatory T cells. (2004) (1110)
- Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1 (2011) (1103)
- The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. (2015) (1068)
- Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity (2005) (1019)
- Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. (2015) (1015)
- Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response (1990) (994)
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. (2016) (976)
- B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells (2001) (904)
- Expression of Programmed Death 1 Ligands by Murine T Cells and APC1 (2002) (892)
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. (2017) (858)
- Does the immune system see tumors as foreign or self? (2003) (794)
- IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway (2009) (785)
- Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. (1991) (758)
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses (2015) (750)
- Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. (2013) (735)
- The role of CD4+ T cell responses in antitumor immunity. (1998) (711)
- Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. (2013) (665)
- Mechanisms of immune evasion by tumors. (2006) (646)
- A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations (1991) (619)
- A fixed site of DNA replication in eucaryotic cells (1980) (612)
- Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. (2009) (611)
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. (2017) (601)
- Immunostimulatory monoclonal antibodies for cancer therapy (2007) (597)
- Cutting Edge: An In Vivo Requirement for STAT3 Signaling in TH17 Development and TH17-Dependent Autoimmunity1 (2007) (582)
- Supercoiled loops and eucaryotic DNA replication (1980) (577)
- Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria (2018) (574)
- Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. (2001) (567)
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses (2016) (516)
- Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody (2012) (502)
- STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade (2015) (500)
- Microbiota organization is a distinct feature of proximal colorectal cancers (2014) (496)
- Persistent Toll-like receptor signals are required for reversal of regulatory T cell–mediated CD8 tolerance (2004) (465)
- Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. (2009) (454)
- Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. (1997) (453)
- Molecular and cellular events of T cell development. (1989) (451)
- LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. (2007) (445)
- Paracrine cytokine adjuvants in cancer immunotherapy. (1995) (432)
- Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity (2006) (431)
- Activation of gamma delta T cells in the primary immune response to Mycobacterium tuberculosis. (1989) (416)
- STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. (2013) (415)
- Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. (2015) (400)
- Neoadjuvant checkpoint blockade for cancer immunotherapy (2020) (399)
- Developing a pro-regenerative biomaterial scaffold microenvironment requires T helper 2 cells (2016) (397)
- The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. (1996) (395)
- Vaccines: Spinning molecular immunology into successful immunotherapy (2002) (374)
- The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. (2015) (370)
- Effects of cyclosporine A on T cell development and clonal deletion. (1988) (357)
- Differential expression of two distinct T-cell receptors during thymocyte development (1987) (356)
- A novel population of T-cell receptor αβ-bearing thymocytes which predominantly expresses a single Vβ gene family (1987) (355)
- Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis. (2019) (349)
- Role of Stat3 in Regulating p53 Expression and Function (2005) (348)
- In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses (2009) (347)
- Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers (2014) (344)
- Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α (2015) (341)
- Alterations of immune response of non-small cell lung cancer with Azacytidine (2013) (335)
- CD4+ T Cell Tolerance to Parenchymal Self-Antigens Requires Presentation by Bone Marrow–derived Antigen-presenting Cells (1998) (326)
- Attrition of T cell memory: selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses. (1999) (325)
- Cellular immune selection with hepatitis C virus persistence in humans (2005) (324)
- Major histocompatibility complex class II‐restricted presentation of a cytosolic antigen by autophagy (2003) (323)
- Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas (2016) (319)
- Molecular events in the induction of a nonresponsive state in interleukin 2-producing helper T-lymphocyte clones. (1987) (310)
- Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. (2000) (308)
- Eos Mediates Foxp3-Dependent Gene Silencing in CD4+ Regulatory T Cells (2009) (306)
- Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. (2014) (300)
- Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. (1998) (290)
- Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. (2005) (286)
- Deletion of self-reactive thymocytes occurs at a CD4+8+ precursor stage (1988) (265)
- Metabolism links bacterial biofilms and colon carcinogenesis. (2015) (260)
- A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours (1995) (259)
- Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C (2005) (255)
- Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. (1998) (255)
- Bacteroides fragilis Toxin Coordinates a Pro-carcinogenic Inflammatory Cascade via Targeting of Colonic Epithelial Cells. (2018) (253)
- In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. (1996) (251)
- Cutting Edge: Expression of Functional CD137 Receptor by Dendritic Cells1 (2002) (249)
- Characterization of murine thymocytes with CDS-associated T-cell receptor structures (1987) (248)
- The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3. (2013) (246)
- Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) (2018) (241)
- Molecular characterization of defective antigen processing in human prostate cancer. (1995) (239)
- Cd40-Independent Pathways of T Cell Help for Priming of Cd8+ Cytotoxic T Lymphocytes (2000) (236)
- Tumor Regression and Allograft Rejection after Administration of Anti-PD-1. (2016) (230)
- Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. (2007) (228)
- Spontaneous Regression of High-Grade Cervical Dysplasia: Effects of Human Papillomavirus Type and HLA Phenotype (2005) (225)
- Cancer immunotherapy comes of age. (2011) (221)
- Exposing the immunology of naked DNA vaccines. (1995) (221)
- Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model (2014) (219)
- Mechanisms regulating PD-L1 expression on tumor and immune cells (2019) (216)
- Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells1 (2009) (216)
- Demonstration of a rational strategy for human prostate cancer gene therapy. (1994) (214)
- A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells. (2010) (213)
- In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression (1994) (213)
- Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade (2015) (212)
- Anti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM (2016) (211)
- Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. (2007) (204)
- TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM (2018) (201)
- Cancer and the Immune System: Basic Concepts and Targets for Intervention. (2015) (200)
- Tc17 CD8 T Cells: Functional Plasticity and Subset Diversity1 (2009) (198)
- A reassessment of the role of B7-1 expression in tumor rejection (1995) (197)
- Characterization of T cell receptor gamma chain expression in a subset of murine thymocytes. (1986) (194)
- Inducing autoimmune disease to treat cancer. (1999) (193)
- A Phase I Trial of a Human Papillomavirus DNA Vaccine for HPV16+ Cervical Intraepithelial Neoplasia 2/3 (2009) (192)
- Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. (2003) (191)
- Perspective: alpha-bugs, their microbial partners, and the link to colon cancer. (2011) (191)
- A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. (2010) (190)
- Metabolic control of the Treg/Th17 axis (2013) (188)
- Differential binding properties of B7-H1 and B7-DC to programmed death-1. (2003) (188)
- Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade (2014) (186)
- LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis1 (2009) (184)
- Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma (2017) (181)
- Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. (1993) (178)
- Design, clinical translation and immunological response of biomaterials in regenerative medicine (2016) (177)
- Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer (2013) (175)
- TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer. (2016) (172)
- Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? (1996) (167)
- In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses (2005) (167)
- Cooperative B7-1/2 (CD80/CD86) and B7-DC Costimulation of CD4+ T Cells Independent of the PD-1 Receptor (2003) (167)
- Immunology beats cancer: a blueprint for successful translation (2012) (162)
- Epigenetic therapy inhibits metastases by disrupting premetastatic niches (2020) (160)
- Carrier detection in X-linked agammaglobulinemia by analysis of X-chromosome inactivation. (1987) (160)
- IL-17 enhances tumor development in carcinogen-induced skin cancer. (2010) (159)
- Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. (2018) (159)
- Treg functional stability and its responsiveness to the microenvironment (2014) (158)
- An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. (2013) (157)
- Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy. (2018) (156)
- Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. (2009) (156)
- HIV and HCV Activate the Inflammasome in Monocytes and Macrophages via Endosomal Toll-Like Receptors without Induction of Type 1 Interferon (2014) (155)
- A new look for the 1990s (1994) (154)
- Loss of epigenetic modification driven by the Foxp3 transcription factor leads to regulatory T cell insufficiency. (2012) (150)
- Immunotherapy earns its spot in the ranks of cancer therapy (2012) (143)
- Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells. (2002) (142)
- Cancer immunotherapy: breaking the barriers to harvest the crop (2004) (141)
- Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers (2021) (138)
- Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors (2016) (135)
- Antigen‐specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein (1998) (134)
- Targeting a neoantigen derived from a common TP53 mutation (2021) (134)
- Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells. (2005) (133)
- Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment (2017) (133)
- High efficiency gene transfer into primary human tumor explants without cell selection. (1993) (132)
- Tissue matrix arrays for high throughput screening and systems analysis of cell function (2015) (131)
- Divergent immune responses to synthetic and biological scaffolds. (2019) (130)
- Stat3 Activity in Melanoma Cells Affects Migration of Immune Effector Cells and Nitric Oxide-Mediated Antitumor Effects1 (2005) (130)
- High-Programmed Death-1 Levels on Hepatitis C Virus-Specific T Cells during Acute Infection Are Associated with Viral Persistence and Require Preservation of Cognate Antigen during Chronic Infection1 (2008) (129)
- B7-DC Regulates Asthmatic Response by an IFN-γ-Dependent Mechanism1 (2004) (129)
- Cellular Vaccine Approaches (2010) (127)
- YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity. (2018) (124)
- Consensus nomenclature for CD8+ T cell phenotypes in cancer (2015) (118)
- Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma (2015) (115)
- Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. (2020) (115)
- Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations. (2019) (115)
- The Myeloid Immune Signature of Enterotoxigenic Bacteroides Fragilis-Induced Murine Colon Tumorigenesis (2016) (115)
- Regulatory T-cell Response to Enterotoxigenic Bacteroides fragilis Colonization Triggers IL17-Dependent Colon Carcinogenesis. (2015) (112)
- Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer (2020) (111)
- The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma (2016) (110)
- Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. (2005) (109)
- Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. (2014) (108)
- The fate of CD4-8- T cell receptor-alpha beta+ thymocytes. (1991) (108)
- In Vivo CD4+ T Cell Tolerance Induction Versus Priming Is Independent of the Rate and Number of Cell Divisions1 (2000) (108)
- Human colon mucosal biofilms from healthy or colon cancer hosts are carcinogenic (2019) (107)
- Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine. (1995) (106)
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses (2017) (106)
- GM-CSF-based cellular vaccines: a review of the clinical experience. (2002) (105)
- Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability (2007) (103)
- Opportunities and challenges in the development of experimental drug combinations for cancer. (2011) (103)
- Biomimetic anisotropic polymeric nanoparticles coated with red blood cell membranes for enhanced circulation and toxin removal (2020) (100)
- Redundant Innate and Adaptive Sources of IL17 Production Drive Colon Tumorigenesis. (2016) (100)
- Inhibition of experimental vasospasm with anti-intercellular adhesion molecule-1 monoclonal antibody in rats. (1997) (100)
- GM-CSF Gene-Modifed Cancer Cell Immunotherapies: Of Mice and Men (2006) (97)
- Cancer vaccines. (1993) (96)
- Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. (2013) (95)
- The relationship of the nuclear matrix to cellular structure and function. (1978) (95)
- Controlled Local Delivery of Interleukin-2 by Biodegradable Polymers Protects Animals from Experimental Brain Tumors and Liver Tumors (2001) (93)
- Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. (2000) (91)
- Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. (1998) (87)
- The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity (2018) (87)
- Expression of LAG‐3 and efficacy of combination treatment with anti‐LAG‐3 and anti‐PD‐1 monoclonal antibodies in glioblastoma (2018) (86)
- New strategies for enhancing the immunogenicity of tumors. (1993) (86)
- Localization of SV40 genes within supercoiled loop domains. (1980) (86)
- Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial (2016) (86)
- Interleukin-36γ–producing macrophages drive IL-17–mediated fibrosis (2019) (85)
- A novel population of T-cell receptor alpha beta-bearing thymocytes which predominantly expresses a single V beta gene family. (1987) (85)
- Immunoglobulin gene rearrangements in remission bone marrow specimens from patients with acute lymphoblastic leukemia. (1986) (83)
- Oral antibiotic use and risk of colorectal cancer in the United Kingdom, 1989–2012: a matched case–control study (2019) (83)
- Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. (2007) (82)
- Radiotherapy augments the immune response to prostate cancer in a time‐dependent manner (2008) (82)
- Therapeutic administration of IL‐15 superagonist complex ALT‐803 leads to long‐term survival and durable antitumor immune response in a murine glioblastoma model (2016) (81)
- CD4+ T Cells Pass Through an Effector Phase During the Process of In Vivo Tolerance Induction (2003) (79)
- A Phase I Clinical Trial of Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected with the GM-CSF Gene for the Treatment of Pancreatic Adenocarcinoma. The Johns Hopkins Oncology Center, Baltimore, Maryland (1998) (79)
- Integrin alpha2 mediates selective metastasis to the liver. (2009) (78)
- PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function (2019) (78)
- Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment (2019) (77)
- Stat3 Activation in Murine Colitis Induced by Enterotoxigenic Bacteroides fragilis (2014) (77)
- B7-DC regulates asthmatic response by an IFN-gamma-dependent mechanism. (2004) (77)
- Antigen‐specific cancer immunotherapy using a GM‐CSF secreting allogeneic tumor cell‐based vaccine (2000) (77)
- Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade (2021) (76)
- Therapeutic vaccination for cancer. (2000) (75)
- New strategies for active immunotherapy with genetically engineered tumor cells. (1992) (75)
- Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting (2015) (75)
- MicroRNA-17 Modulates Regulatory T Cell Function by Targeting Co-regulators of the Foxp3 Transcription Factor. (2016) (74)
- Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer (2013) (74)
- Therapeutic potential of protein and adjuvant vaccinations on tumour growth. (2001) (74)
- Essential role of TNF family molecule LIGHT as a cytokine in the pathogenesis of hepatitis. (2006) (74)
- Bacteroides fragilis Toxin Coordinates a Pro-carcinogenic Inflammatory Cascade via Targeting of Colonic Epithelial Cells. (2018) (74)
- Elimination of Hepatic Metastases of Colon Cancer Cells via p53-Independent Cross-Talk between Irinotecan and Apo2 Ligand/TRAIL (2004) (74)
- Bispecific antibodies targeting mutant RAS neoantigens (2021) (73)
- Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. (1996) (72)
- A biologic scaffold–associated type 2 immune microenvironment inhibits tumor formation and synergizes with checkpoint immunotherapy (2019) (72)
- IL-17 and immunologically induced senescence regulate response to injury in osteoarthritis. (2020) (72)
- DeepTCR is a deep learning framework for revealing sequence concepts within T-cell repertoires (2021) (71)
- Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer (2020) (71)
- Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. (2003) (71)
- Sequence analysis of nuclear matrix associated DNA from rat liver. (1980) (70)
- Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial. (2013) (70)
- HLA-DQB1*02–Restricted HPV-16 E7 Peptide–Specific CD4+ T-Cell Immune Responses Correlate with Regression of HPV-16–Associated High-Grade Squamous Intraepithelial Lesions (2007) (69)
- Thymus-dependent and thymus-independent developmental pathways for peripheral T cell receptor-gamma delta-bearing lymphocytes. (1988) (69)
- Cyclosporin A inhibits positive selection and delays negative selection in alpha beta TCR transgenic mice. (1994) (69)
- Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. (2020) (69)
- Cross-linking the B7 Family Molecule B7-DC Directly Activates Immune Functions of Dendritic Cells (2002) (68)
- Interleukin 17 and senescent cells regulate the foreign body response to synthetic material implants in mice and humans (2020) (68)
- Bone marrow-derived cells present MHC class I-restricted tumour antigens in priming of antitumour immune responses. (1994) (67)
- Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer (2019) (66)
- A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events. (2018) (66)
- Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. (1992) (65)
- Antigen-Specific Blockade of T Cells In Vivo Using Dimeric MHC Peptide1 (2001) (65)
- Immunology: T cells and tumours (2001) (64)
- Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy (2017) (63)
- Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade (2019) (63)
- Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats. (2000) (63)
- Immunotherapy of established tumors using bone marrow transplantation with antigen gene–modified hematopoietic stem cells (2003) (61)
- Feedback inhibition of calcineurin and Ras by a dual inhibitory protein Carabin (2007) (61)
- Proliferation and production of IL-2 and B cell stimulatory factor 1/IL-4 in early fetal thymocytes by activation through Thy-1 and CD3. (1988) (61)
- Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. (1998) (61)
- Early genetic events in T cell development analyzed by in situ hybridization (1987) (60)
- Intratumoral Administration of TLR4 Agonist Absorbed into a Cellular Vector Improves Antitumor Responses (2011) (59)
- The role of STAT3 activation in modulating the immune microenvironment of GBM (2012) (59)
- The Scaffold Immune Microenvironment: Biomaterial-Mediated Immune Polarization in Traumatic and Nontraumatic Applications. (2016) (59)
- Stress, NK Receptors, and Immune Surveillance (2001) (59)
- AACR Cancer Progress Report 2013 (2013) (58)
- Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. (1999) (58)
- Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. (1996) (58)
- Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells. (2003) (57)
- Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma (2018) (57)
- Murine tumor antigens: is it worth the search? (1996) (57)
- Simplified high-sensitivity sequencing of a major histocompatibility complex class I-associated immunoreactive peptide using matrix-assisted laser desorption/ionization mass spectrometry. (1995) (57)
- Inhibition of vasospasm with lymphocyte function-associated antigen-1 monoclonal antibody in a femoral artery model in rats. (2002) (55)
- A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. (1998) (54)
- Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes. (2006) (54)
- Expression profile and in vitro blockade of programmed death‐1 in human papillomavirus–negative head and neck squamous cell carcinoma (2015) (54)
- Naturally Occurring Human IgM Antibody That Binds B7-DC and Potentiates T Cell Stimulation by Dendritic Cells 1 (2003) (53)
- Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination (2015) (52)
- T cells take aim at cancer (2002) (51)
- PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment (2014) (51)
- Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies (2008) (51)
- Non-toxigenic Bacteroides fragilis (NTBF) administration reduces bacteria-driven chronic colitis and tumor development independent of polysaccharide A (2018) (49)
- Peripheral murine CD3+, CD4-, CD8- T lymphocytes express novel T cell receptor gamma delta structures. (1988) (49)
- Functional characterization of CD4+ T-cell receptors cross-reactive for SARS-CoV-2 and endemic coronaviruses. (2021) (49)
- Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes. (2002) (49)
- B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma. (2008) (48)
- Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines. (1997) (47)
- Tumour antigens. A new look for the 1990s. (1994) (47)
- Synergistic Effect of a Granulocyte-Macrophage Colony-Stimulating Factor–Transduced Tumor Vaccine and Systemic Interleukin-2 in the Treatment of Murine Colorectal Cancer Hepatic Metastases (2003) (46)
- Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine. (2005) (46)
- Erratum: Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses (Cell (2015) 162(5) (974–986) (S009286741500848X) (10.1016/j.cell.2015.07.011)) (2017) (46)
- PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation (2014) (46)
- Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma (2015) (45)
- A requirement of STAT3 DNA binding precludes Th-1 immunostimulatory gene expression by NF-κB in tumors. (2011) (44)
- TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors (2018) (44)
- Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system (2018) (44)
- Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti–PD-1 in melanoma (2019) (43)
- Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling. (2006) (43)
- Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation. (2002) (43)
- Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors (2019) (41)
- Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus (2008) (41)
- Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor (2002) (40)
- Costimulator B7-DC Attenuates Strong Th2 Responses Induced by Nippostrongylus brasiliensis (2010) (40)
- Tumor Recognition and Self-Recognition Induce Distinct Transcriptional Profiles in Antigen-Specific CD4 T Cells 1 (2009) (40)
- Immunotherapy with cytokine gene‐transduced tumor cells: the next wave in gene therapy for cancer (1992) (39)
- The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures (2020) (37)
- Live attenuated Listeria monocytogenes effectively treats hepatic colorectal cancer metastases and is strongly enhanced by depletion of regulatory T cells. (2007) (36)
- Neoadjuvant nivolumab in early-stage, resectable non-small cell lung cancers. (2017) (36)
- Targeting public neoantigens for cancer immunotherapy (2021) (36)
- Lymphoid reconstitution after transplantation of congenic hematopoietic cells in busulfan-treated mice. (1991) (35)
- Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial (2021) (35)
- Molecular mechanisms for lineage commitment in T cell development. (1990) (34)
- Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy. (2017) (34)
- Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. (1995) (34)
- Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma (2020) (34)
- Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology (2005) (33)
- PD-L1 expression in medulloblastoma: an evaluation by subgroup (2018) (33)
- Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 (2019) (33)
- Ubiquitin‐dependent regulation of Foxp3 and Treg function (2015) (33)
- Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor. (2013) (33)
- Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells (2010) (32)
- HEMATOPOIETIC CELL TRANSPLANTATION IN THE TWITCHER MOUSE: THE EFFECTS OF PRETRANSPLANT CONDITIONING WITH GRADED DOSES OF BUSULFAN (1993) (31)
- The intestinal microbiome influences checkpoint blockade (2018) (31)
- Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype. (2019) (31)
- The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints (2015) (31)
- The antitumor immune response as a problem of self-nonself discrimination: Implications for immunotherapy (1993) (30)
- Inhibition of activation-induced death of dendritic cells and enhancement of vaccine efficacy via blockade of MINOR. (2009) (30)
- Erratum: Bacteroides fragilis Toxin Coordinates a Pro-carcinogenic Inflammatory Cascade via Targeting of Colonic Epithelial Cells (Cell Host & Microbe (2018) 23(2) (203–214.e5) (S1931312818300428) (10.1016/j.chom.2018.01.007)) (2018) (29)
- Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy (2019) (29)
- Intracranial Paracrine Interleukin-2 Therapy Stimulates Prolonged Antitumor Immunity That Extends Outside the Central Nervous System (2000) (28)
- Thymic selection. (1992) (28)
- Tumor-Associated Antigen Expressing Listeria monocytogenes Induces Effective Primary and Memory T-Cell Responses Against Hepatic Colorectal Cancer Metastases (2011) (28)
- Cancer vaccines (1998) (28)
- Are the IL-2 Receptors Expressed in the Murine Fetal Thymus Functional? (1990) (28)
- TLR agonist–Stat3 siRNA conjugates: cell-specific gene silencing and enhanced antitumor immune responses (2009) (27)
- Activation properties of T cell receptor-gamma delta hybridomas expressing diversity in both gamma- and delta-chains. (1988) (27)
- Advances in gene therapy for malignant melanoma. (2002) (27)
- Phase II experience with MDX-1106 (Ono-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. (2009) (27)
- Immunologic consequences of signal transducers and activators of transcription 3 activation in human squamous cell carcinoma. (2010) (27)
- Neoadjuvant nivolumab in resectable non-small cell lung cancer: Extended follow-up and molecular markers of response. (2019) (26)
- A Safety and Feasibility Study of an Allogeneic Colon Cancer Cell Vaccine Administered with a Granulocyte–Macrophage Colony Stimulating Factor–Producing Bystander Cell Line in Patients with Metastatic Colorectal Cancer (2014) (26)
- PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors. (2012) (26)
- Baculovirus-Infected Insect Cells Expressing Peptide-MHC Complexes Elicit Protective Antitumor Immunity1 (2008) (26)
- IFN-producing killer dendritic cells are antigen-presenting cells endowed with T-cell cross-priming capacity. (2009) (25)
- Limitations of adenovirus‐mediated interleukin‐2 gene therapy for oral cancer (1999) (25)
- CD 40-independent Pathways of T Cell Help for Priming of CD 8 1 Cytotoxic T Lymphocytes (2000) (25)
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. (2018) (25)
- Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes (2021) (24)
- Mouse PVRIG Has CD8+ T Cell–Specific Coinhibitory Functions and Dampens Antitumor Immunity (2019) (24)
- Genetically Engineered Tumor Cell Vaccine in a Head and Neck Cancer Model (2003) (24)
- Targeting loss of heterozygosity for cancer-specific immunotherapy (2021) (24)
- Tumor‐specific CD4+ T cells from a patient with renal cell carcinoma recognize diverse shared antigens (2005) (23)
- Neoadjuvant nivolumab plus concurrent chemoradiation in stage II/III esophageal/gastroesophageal junction cancer. (2019) (23)
- DeepTCR: a deep learning framework for revealing structural concepts within TCR Repertoire (2018) (23)
- Lack of Coreceptor Allows Survival of Chronically Stimulated Double-Negative α/β T Cells (2001) (23)
- Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair‐Deficient Prostate Cancer (2020) (23)
- Hepatitis C Virus Immune Escape via Exploitation of a Hole in the T Cell Repertoire1 (2008) (22)
- Tumor immunology--towards a paradigm of reciprocal research. (2002) (22)
- Metastasis-promoting immunity: when T cells turn to the dark side. (2009) (21)
- Self-reactive T cells are present in the peripheral lymphoid tissues of cyclosporin A-treated mice. (1992) (21)
- Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial (2021) (21)
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (2023) (20)
- DeepTCR: a deep learning framework for understanding T-cell receptor sequence signatures within complex T-cell repertoires (2018) (20)
- Aging‐associated B7‐DC+ B cells enhance anti‐tumor immunity via Th1 and Th17 induction (2012) (20)
- Caspase-1 from Human Myeloid-Derived Suppressor Cells Can Promote T Cell–Independent Tumor Proliferation (2018) (20)
- Dexamethasone Mediated Inhibition of Local IL-2 Immunotherapy is Dose Dependent in Experimental Brain Tumors (2004) (19)
- Microenvironment and Immunology Evidence for a Role of the PD-1 : PD-L 1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma (2013) (19)
- Genetically Engineered Tumor Vaccines (1993) (19)
- Aplastic crisis due to extensive bone marrow necrosis in sickle cell disease. (1982) (18)
- Kidney retransplantation after anti–programmed cell death‐1 (PD‐1)–related allograft rejection (2020) (18)
- Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer (2022) (18)
- Shift from pStat6 to pStat3 Predominance Is Associated with Inflammatory Bowel Disease‐Associated Dysplasia (2012) (17)
- Autologous reconstitution of human cancer and immune system in vivo (2016) (17)
- Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer (2020) (17)
- Immunotherapy: it takes a village. (2014) (17)
- Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer model. (2013) (17)
- Genomic and clinical characterization of pulmonary‐only metastatic prostate cancer: A unique molecular subtype (2019) (16)
- An Immunodominant MHC Class II-Restricted Tumor Antigen Is Conformation Dependent and Binds to the Endoplasmic Reticulum Chaperone, Calreticulin1 (2001) (16)
- Tyrosine kinase triggering in thymocytes undergoing positive selection (1992) (16)
- A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors. (2013) (16)
- Therapeutic Targeting of Checkpoint Receptors within the DNAM-1 Axis. (2021) (16)
- Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer. (2016) (15)
- TCR β chain–directed bispecific antibodies for the treatment of T cell cancers (2021) (15)
- Treament of liver metastases from colon carcinoma with autologous tumor vaccine expressing granulocyte‐macrophage colony‐stimulating factor (1999) (15)
- YAP Attenuates CD8 T Cell-Mediated Anti-tumor Response (2020) (15)
- A set of genes selectively expressed in murine dendritic cells: utility of related cis-acting sequences for lentiviral gene transfer. (2003) (15)
- Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer (2021) (15)
- Update: Releasing the Brakes on Antitumor Immune Response (1996) (15)
- Distinct mechanisms of tumor resistance to NK killing: of mice and men. (2015) (14)
- A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors (2021) (14)
- NSCLC, early stageNeoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer (2016) (14)
- Abstract NG01: Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer (2017) (14)
- Recombinant human papillomavirus type 16 E7 protein as a model antigen to study the vaccine potential in control and E7 transgenic mice. (2001) (13)
- Spatial Distribution of Tumor Vaccine Improves Efficacy (2003) (13)
- Genome‐wide investigation of intragenic DNA methylation identifies ZMIZ1 gene as a prognostic marker in glioblastoma and multiple cancer types (2019) (13)
- Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response. (2012) (13)
- Concepts of immunotherapy for glioma (2015) (13)
- Melanoma and immunotherapy bridge 2015 (2016) (13)
- Tc 17 CD 8 T Cells : Functional Plasticity and Subset Diversity 1 (2017) (12)
- Nutritional Status as a Predictive Biomarker for Immunotherapy Outcomes in Advanced Head and Neck Cancer (2021) (12)
- 143 The Combination of anti-TIM-3 and anti-PD-1 Checkpoint Inhibitors With Focused Radiation Resulted in a Synergistic Antitumor Immune Response in a Preclinical Glioma Model (2015) (12)
- Selective association between MHC class I-restricted T cell receptors, CDS, and activated tyrosine kinases on thymocytes undergoing positive selection. (1992) (12)
- A murine thymocyte clone expressing γδ T cell receptor mediates natural killer-like cytolytic function and TH1-like lymphokine production (1990) (12)
- Lack of coreceptor allows survival of chronically stimulated double-negative alpha/beta T cells: implications for autoimmunity. (2001) (12)
- Treatment of liver metastases from colon carcinoma with autologous tumor vaccine expressing granulocyte-macrophage colony-stimulating factor. (1999) (12)
- Vaccines to Treat Drug Addiction (2004) (12)
- AI-MHC: an allele-integrated deep learning framework for improving Class I & Class II HLA-binding predictions (2018) (11)
- A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors. (2014) (11)
- Gene therapy: its potential applications in the treatment of renal-cell carcinoma. (1995) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- T cell regulation (1995) (10)
- Gene Therapy for Experimental Brain Tumors Using a Xenogenic Cell Line Engineered to Secrete hIL-2 (2003) (10)
- Integrin A2 Mediates Selective Metastasis to the Liver (2009) (10)
- Tumor‐specific CD8+ T lymphocytes derived from the peripheral blood of prostate cancer patients by in vitro stimulation with autologous tumor cell lines (2002) (9)
- PD-1+ Monocytes Mediate Cerebral Vasospasm Following Subarachnoid Hemorrhage. (2020) (9)
- An Immunogenomic Investigation of Oral Cavity Squamous Cell Carcinoma in Patients Aged 45 Years and Younger (2020) (9)
- Phase II neoadjuvant and immunologic study of B7-H3 targeting with enoblituzumab in localized intermediate- and high-risk prostate cancer. (2018) (9)
- Interleukin-17 and senescence regulate the foreign body response (2019) (9)
- Comparative analysis of paracrine immunotherapy in experimental brain tumors. (2000) (8)
- Recombinant BCG overexpressing a STING agonist elicits trained immunity and improved antitumor efficacy in non-muscle invasive bladder cancer (2020) (8)
- Microenvironment and Immunology Immune InhibitoryMolecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape (2012) (8)
- Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens (2021) (8)
- Anti‐tumor effects of endogenous prostate cancer‐specific CD8 T cells in a murine TCR transgenic model (2012) (8)
- Molecular engineering of the antitumor immune response. (1992) (8)
- Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) (2019) (8)
- Can bone marrow-derived thymic stromal cells mediate the positive selection of class I-restricted T cells? (1996) (7)
- Hypoxia-inducible factor 1 (2012) (6)
- STAT Proteins as Molecular Targets for Cancer Therapy (2003) (6)
- Comparison of next generation sequencing, droplet digital PCR, and quantitative real-time PCR for the earlier detection and quantification of HPV in HPV-positive oropharyngeal cancer. (2022) (6)
- Abstract 451: The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints (2015) (6)
- Taming the sinister side of BMT: Dr. Jekyll and Mr. Hyde (1997) (6)
- Association of Tumor Site With the Prognosis and Immunogenomic Landscape of Human Papillomavirus-Related Head and Neck and Cervical Cancers. (2021) (6)
- Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma (2015) (5)
- ExCYT: A Graphical User Interface for Streamlining Analysis of High-Dimensional Cytometry Data. (2019) (5)
- Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response. (2012) (5)
- Corrigendum: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells (2004) (5)
- Targeted gene therapy to antigen-presenting cells in the central nervous system using hematopoietic stem cells (2005) (5)
- A Requirement of STAT 3 DNA Binding Precludes Th1 Immunostimulatory Gene Expression by NFk B in Tumors (2011) (5)
- The Neurotrophic Factor Neuritin Maintains and Promotes the Function of Regulatory T cells in Autoimmunity and Cancer (2016) (5)
- Tumor reactive T cells get a boost (2002) (5)
- Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures (2021) (5)
- Expression of Programmed Death 1 Ligands (2013) (5)
- Abstract LB-193: Phase I study of safety, tolerability, pharmacokinetics, and pharmacodynamics of AMP-224 (B7-DC Fc fusion protein) in a regimen containing cyclophosphamide (CTX) in patients with advanced solid tumors. (2013) (5)
- Discovery of COM701, a therapeutic antibody targeting the novel immune checkpoint PVRIG, for the treatment of cancer. (2017) (5)
- The prognostic impact of pathologic lymph nodes in HPV-positive oropharyngeal cancers. (2019) (5)
- Abstract 581: Discovery and development of COM701, a therapeutic antibody targeting the novel immune checkpoint PVRIG (2017) (5)
- Recombinant BCG overexpressing STING agonist elicits trained immunity and improved antitumor efficacy in non-muscle invasive bladder cancer (2020) (5)
- Abstract 446: Differential expression of immuno-regulatory genes associated with PD-L1 display: Implications for clinical blockade of the PD-1/PD-L1 pathway in melanoma. (2013) (4)
- Combination immunotherapy: Where do we go from here? (2015) (4)
- Timeline: a decade of advances in immunotherapy (2011) (4)
- TGF-β1 enhances T-cell PD-1 expression through a Smad3-dependant increase in transcription. (IRM4P.499) (2014) (4)
- Live-attenuated L. monocytogenes encoding mesothelin for immunotherapy of patients with pancreas and ovarian cancers (2007) (4)
- Risk factors for human papillomavirus‐positive nonoropharyngeal squamous cell carcinoma (2020) (4)
- Single cell RNA-seq in regenerative and fibrotic biomaterial environments defines new macrophage subsets (2019) (4)
- Homozygous α Thalassemia/HB G Philadelphia (1982) (4)
- Neoadjuvant immunotherapy prior to surgery for mucosal head and neck squamous cell carcinoma: Systematic review (2021) (4)
- Persistent mutation burden drives sustained anti-tumor immune responses (2023) (3)
- MICROENVIRONMENT AND IMMUNOLOGY 4030 Microbiota Modulate Tumoral Immune Surveillance in Lung through a gdT17 Immune Cell-Dependent Mechanism (2014) (3)
- PD-1:PD-L1(B7-H1) pathway in adaptive resistance: A novel mechanism for tumor immune escape in human papillomavirus-related head and neck cancers. (2012) (3)
- Integrative tumor and immune cell multi-omic analyses to predict melanoma response to immune checkpoint blockade. (2020) (3)
- Autoimmunity Epitope Results in Tumor Rejection But Not Activation of Low Avidity CTL Specific for a Self (1998) (3)
- Immune checkpoints expression in MSI versus MSS colorectal cancers and their potential therapeutic implications. (2014) (3)
- Abstract CT079: Neoadjuvant PD-1 blockade in resectable lung cancer (2018) (3)
- Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions (2022) (3)
- Phase II study of nivolumab and relatlimab in advanced mismatch repair deficient (dMMR) cancers resistant to prior PD-(L)1 inhibition. (2020) (3)
- SARS-CoV-2 vaccination diversifies the CD4+ spike-reactive T cell repertoire in patients with prior SARS-CoV-2 infection (2022) (3)
- Maturation of cancer vaccines. A meeting report on 'Cancer Vaccines 1996,' sponsored by the Cancer Research Institute, held October 7-9, 1996. (1997) (3)
- Nitric Oxide-Mediated Antitumor Effects Migration of Immune Effector Cells and Stat3 Activity in Melanoma Cells Affects (2005) (3)
- Modified STING-activating cyclic dinucleotide derivatives significantly enhance the anti-tumor activity of therapeutic vaccines (2013) (3)
- Adjuvant Vaccine Therapy in Combination with Radiation for Treatment of Prostate Cancer: Preclinical Validation in a Mouse Model of Prostate Cancer (2008) (2)
- Abstract 2495: STING agonists formulated into cancer vaccines (STINGVAX) can cure established tumor resistant to immune checkpoint blockade by activating NK cells (2015) (2)
- Genomic characterization of pulmonary-metastatic prostate cancer: A unique molecular subtype. (2019) (2)
- Molecular analysis of a pro‐T cell clone transformed by Abelson‐murine leukemia virus, displaying progressive γδ T cell receptor gene rearrangement and surface expression (1992) (2)
- 627P Phase II neoadjuvant trial of the anti–B7-H3 antibody, enoblituzumab, in men with localized prostate cancer: Safety, efficacy and immune correlates (2021) (2)
- Building the bionic T cell (2007) (2)
- Supraphysiological testosterone induces ferroptosis and activates NF-kappaB mediated immune pathways in prostate cancer through nucleophagy (2020) (2)
- Risk Factors for Human Papillomavirus-Positive Nonoropharyngeal Squamous Cell Carcinoma (2020) (2)
- Author Correction: DeepTCR is a deep learning framework for revealing sequence concepts within T-cell repertoires (2021) (2)
- T cell receptor gamma/delta chain diversity (1988) (2)
- Combined next generation sequencing and flow cytometry analysis of an anti-PD-L1 partial responder over time: An exploration into mechanisms of PD-L1 activity and resistance (2017) (2)
- Abstract 1736: The combination of CXCR4 and checkpoint receptor inhibition improves survival in an orthotopic murine glioma model (2018) (2)
- Abstract 4573: STINGVAX - A novel tumor vaccine with cyclic dinucleotides - can induce potent anti-tumor responsesin vivo. (2013) (2)
- A second generation IL-2 receptor-targeted diphtheria fusion toxin exhibits anti-tumor activity and synergy with anti-PD-1 in melanoma (2018) (2)
- Transfer learning of an in vivo-derived senescence signature identifies conserved and tissue-specific senescence across species and diverse pathologies (2022) (2)
- Abstract 517: Supraphysiological androgens activate innate immune signaling in prostate cancer (2019) (2)
- Abstract 4619: Epigenetic therapy and sensitization of lung cancer to immunotherapy. (2013) (2)
- A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study. (2023) (2)
- P2.04-24 Transcriptional Profiling of Neoantigen Specific T Cells in Resectable NSCLC Treated with Neoadjuvant Anti-PD-1 (2019) (2)
- Combining Anti-PD-1 (B7-H1) Immunotherapy with Stereotactic Radiosurgery in a Mouse Orthotopic Glioblastoma Model (2011) (2)
- Abstract 4750: The immunosuppressive tumor microenvironment (TME) in nasopharyngeal carcinoma: implications for immunotherapy (2018) (2)
- Analysis of T-cell receptor gamma chain expression in the thymus. (1987) (2)
- TNFα and radio-resistant stromal cells are essential for therapeutic efficacy of cyclic dinucleotide STING agonists in non-immunogenic tumors (2018) (2)
- Glycolipid antigens for treating hepatic colorectal cancer metastases and their effect on the therapeutic efficacy of live attenuated Listeria monocytogenes. (2012) (2)
- 16 Cancer Immunotherapy (1999) (1)
- High-dimensional Cytometry (ExCYT) and Mass Spectrometry of Myeloid Infiltrate in Clinically Localized Clear Cell Renal Cell Carcinoma Identifies Novel Potential Myeloid Targets for Immunotherapy (2020) (1)
- Introduction: Cancer and the immune system (1996) (1)
- Cognate Antigen during Chronic Infection Persistence and Require Preservation of Acute Infection Are Associated with Viral Hepatitis C Virus-Specific T Cells during High-Programmed Death-1 Levels on Sette (2008) (1)
- Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors (2022) (1)
- Translation of cancer immunotherapies (2004) (1)
- Abstract 6584: The ‘AstroPath' platform for spatially resolved, single cell analysis of the tumor microenvironment (TME) using multispectral immunofluorescence (mIF) (2020) (1)
- Controlled delivery of cytokines for therapeutic cancer vaccination (1995) (1)
- Feasibility of human gene therapy for renal cell carcinoma (1994) (1)
- Immune checkpoints in MSI and CSI colorectal cancers and their translational implications (2013) (1)
- Stimulation by Dendritic Cells That Binds B7-DC and Potentiates T Cell Naturally Occurring Human IgM Antibody (2013) (1)
- 506 The tumor immune microenvironment of metastatic osteosarcoma is marked by lymphocyte exclusion and impacts patient progression-free survival (2020) (1)
- IT-21PD-1 BLOCKADE SHOWS SYNERGISTIC SURVIVAL, ANTI-TUMOR IMMUNE RESPONSE AND LONG-TERM MEMORY WITH INTERSTITIAL BUT NOT SYSTEMIC CHEMOTHERAPY: STUDY IN A MURINE GLIOBLASTOMA MODEL. (2014) (1)
- TH17 cells and early pancreatic tumorigenesis. (2013) (1)
- Abstract 77: A Phase I Open-Label Study Evaluating the Safety of Acellular Adipose Tissue (AAT), a Novel Soft Tissue Reconstruction Solution, in Healthy Volunteers (2017) (1)
- Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial (2023) (1)
- Interrogation of T Cell–enriched Tumors Reveals Prognostic and Immunotherapeutic Implications of Polyamine Metabolism (2021) (1)
- MA04.11 Neoantigen Targeting and T Cell Reshaping in Resectable NSCLC Patients Treated with Neoadjuvant PD-1 Blockade (2018) (1)
- Delivery of cytokines by microencapsulated transduced cells (1994) (1)
- Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 (2019) (1)
- Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection (2022) (1)
- Brain Tumors Chemotherapy Is Synergistic in the Treatment of Experimental Paracrine Immunotherapy with Interleukin-2 and Local Updated (2000) (1)
- IMMU-18. IMMUNOGENOMIC RESPONDER PHENOTYPE FROM A PHASE I TRIAL OF ANTI-LAG3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM (2019) (1)
- Local interleukin-2 delivery eradicates brain and liver tumors (1998) (1)
- SUPERCOILED LOOPS AND TRANSCRIBING GENES (1982) (1)
- Enterotoxigenic Bacteroides fragilis induces oncogenic regulatory T cells (TUM9P.1000) (2015) (1)
- Homozygous alpha thalassemia/Hb G Philadelphia. (1982) (1)
- Recombinant Technology Peptide – h 2-microglobulin – MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC – Ig complexes (2002) (1)
- Micromanaging lupus nephritis: miR17-92 modulates TFH development and regulatory T cell activity (2017) (1)
- Translation of cancer immunotherapies (2004) (1)
- T Cell Tolerance to Parenchymal Self-Antigens Requires Presentation by Bone Marrow–derived Antigen-presenting Cells (1998) (1)
- GM-CSF microspheres in cancer immunotherapy - A mechanistic study of the vaccine site (1996) (1)
- 90 COMBINING ANTI-PD-1 IMMUNOTHERAPY WITH STEREOTACTIC RADIOSURGERY IN A MOUSE ORTHOTOPIC GLIOBLASTOMA MODEL (2012) (1)
- Abstract PR9: Granulocyte macrophage colony stimulating factor (GM-CSF) pancreas tumor vaccine in combination with blockade of PD-1 in a preclinical model of pancreatic cancer. (2013) (1)
- A murine thymocyte clone expressing gamma delta T cell receptor mediates natural killer-like cytolytic function and TH1-like lymphokine production. (1990) (1)
- Erratum to: PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment (2016) (1)
- 6 – Cancer Immunology (2014) (1)
- Molecular analysis of a pro-T cell clone transformed by Abelson-murine leukemia virus, displaying progressive gamma delta T cell receptor gene rearrangement and surface expression. (1992) (1)
- Regulatory T cells session 1(WS-045a) Chairpersons: Sayuri Yamazaki, Steven Ziegler (2010) (1)
- Impact of Corticosteroids on the Efficacy of Anti-PD-1 Therapy for Tumors Located Within or Outside the Central Nervous System (2018) (1)
- Tumor-Targeted Adenovirus Elicits Anti-Tumor Immune Response with Limited Systemic Toxicity (2005) (1)
- Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers (2021) (1)
- The biologic scaffold immune microenvironment inhibits tumor formation and synergizes with immunotherapy (2019) (1)
- Stat3 and Th17-mediated colitis promotes regional tumorigenesis in response to a common commensal bacterium: role of Foxp3+ Treg/Th17 balance (90.17) (2010) (0)
- Seventh Americas Hepatopancreatobiliary Congress ANNUAL SCIENTIFIC SESSION & POST GRADUATE PROGRAM April 19-22, 2007 Bally's Hotel Las Vegas, Nevada. (2007) (0)
- 681 Single pipeline re-analysis revises microbiome associations with anti-tumor response to checkpoint inhibitors (2020) (0)
- Cyclic dinucleotides (CDNs) reversed T cells tolerance in anti-tumor immunotherapy (2015) (0)
- Characterization of Mesothelin-Specific T Cell Responses in Healthy Individuals (2005) (0)
- Targeting of immunogenic by lysosomes (1994) (0)
- Abstract 1393: Persistent mutation burden drives sustained anti-tumor immune responses in human cancers (2023) (0)
- Virulence of Enterotoxigenic Bacteroides Fragilis (ETBF) Strains is B. Fragilis Toxin (BFT) Isoform Dependent (2011) (0)
- 245: Regression of Prostate Cancer in Animals Treated with Donor Lymphocyte Infusion (DLI) and a Cell Based Tumor Vaccine after Conditioning with a Single Dose of Cyclophosphamide (2005) (0)
- Abstract 4973: The immunosuppressive tumor microenvironment of metastatic osteosarcoma inhibits the cytotoxic effect of tumor-infiltrating lymphocytes (2019) (0)
- M1999 Enterotoxigenic Bacteroides Fragilis Colonic Infection Promotes Colon Tumorigenesis in APCMIN/+ Mice via Activation of TH17 T Cell Responses (2009) (0)
- Abstract 2566: Activation of tumor-initiated T cell priming and tumor destruction with potent STING-activating cyclic dinucleotide derivatives (2014) (0)
- Optimizing the delivery of chemotherapy in the setting of immunotherapy in a preclinical glioblastoma model (2015) (0)
- Synthetic Cytokine Delivery Systems for Cancer Immunotherapy (1998) (0)
- Analysis of Immune Response Induced by Tumors Engineered to Secrete Cytokines (1995) (0)
- Abstract B13: Development of a low-cost method for collecting fecal samples in clinical trials (2020) (0)
- Abstract A14: Meta-analysis improves identification of microbiome associations with antitumor response in melanoma, lung, and kidney cancer patients treated with checkpoint inhibitors (2020) (0)
- The role of PD-1 in human CD8 prostate infiltrating lymphocytes. (66.12) (2011) (0)
- Nucleic Acids Research (2003) (0)
- Abstract 595: Distinct tumor infiltrating Treg lineages are associated with response to anti-PD1 checkpoint blockade in NSCLC (2022) (0)
- Using Dimeric MHC Peptide Antigen-Specific Blockade of T Cells In Vivo (2001) (0)
- THE EFFECTS OF BIOLOGIC AND SMALL MOLECULE INHIBITOR THERAPY ON THE MUCOSAL IMMUNE SYSTEM IN ULCERATIVE COLITIS (2023) (0)
- Helminth egg derivatives as pro-regenerative immunotherapies (2022) (0)
- Abstract 2935: Modulation of immune checkpoint B7-H1/B7-DC/PD-1 interaction in combination with live attenuatedListeria monocytogenesexpressing a tumor associated antigen effectively treats hepatic colorectal cancer metastases (2010) (0)
- Dendritic Cells and Coregulatory Signals: Immune Checkpoint Blockade to Stimulate Immunotherapy (2007) (0)
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab (2023) (0)
- Tumor Histological Grade and Immunotherapy Response in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. (2022) (0)
- DynamicsofTumorand ImmuneResponsesduring Immune Checkpoint Blockade in Non–Small Cell Lung Cancer (2019) (0)
- Abstract 4444: Deep learning of the immune synapse (2019) (0)
- LAB-IMMUNOLOGY RESEARCH (2012) (0)
- Abstract 5031: Effects of BRAF and MEK inhibitors, dabrafenib and trametinib, on the immune system and in combination with immunomodulatory antibodies targeting PD1, PD-L1 and CTLA-4 (2014) (0)
- Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer (2022) (0)
- The neurotrophic factor Neuritin regulates T cell anergy and T regulatory cell function (2022) (0)
- Interleukin-2 Gene Therapy for Established Oral Tumors: Limitations in a Murine Model (1997) (0)
- M1997 CD4+ Lymphocytes Regulate Colonic Tumor Formation in MIN Mice Colonized with Enterotoxigenic Bacteroides Fragilis (ETBF) (2009) (0)
- New strategies for therapy of breast cancer (2004) (0)
- Abstract A141: The vigorous immune microenvironment of microsatellite instable colon cancer isbalanced by multiple counter-inhibitory checkpoints (2016) (0)
- Patent Number : 45 Date of Patent : 5 , 633 , 234 May 27 , 1997 (2017) (0)
- Abstract 2115: Glutamine blockade via prodrug JHU083 reprograms immunosuppressive tumor associated macrophages (TAMs) and drives tumor immunity in urologic cancers (2022) (0)
- Melanoma and immunotherapy bridge 2015 (2016) (0)
- W1809 Activated STAT3 is a Marker of Neoplastic Transformation in IBD (2010) (0)
- STAT3 Signaling in Donor-Derived CD4 + T-Cells Plays a Critical Role in the Induction of Acute and Chronic GVHD in Murine Models of alloBMT. (2007) (0)
- Su.98. Mechanisms of Immune Privilege in High Grade Cervical Dysplasia (2008) (0)
- K 3 Tumor ‐ intrinsic beta ‐ catenin signaling mediates tumor ‐ immune avoidance (2016) (0)
- Science Journals — AAAS (2020) (0)
- Abstract 5033: Azacitidine pretreatment sensitizes NSCLC cells to interferon-γ (2015) (0)
- Enterotoxigenic Bacteroides fragilis induce large bowel inflammation and Th17 response in wild-type C57BL/6 mice: O-013. (2008) (0)
- Adoptive transfer of Tc17 CD8 T cells as an approach to elicit a better immune response to vaccination (165.3) (2012) (0)
- Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma (2016) (0)
- Stat3 underlies IL-23-mediated suppression of anti-tumor immunity (2008) (0)
- W1187 STAT3 Is Activated Throughout the Gastrointestinal Tract in Enterotoxigenic Bacteroides Fragilis Induced Colitis (2008) (0)
- Abstract 1312: Transcriptional signatures associated with lack of response to anti-PD-1 therapy in patients with renal cell carcinoma (2015) (0)
- Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting (2015) (0)
- allogeneic bone marrow chimeras Successful therapy of metastatic cancer using tumor vaccines in mixed (2013) (0)
- Abstract LB-154: Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small cell lung carcinoma (NSCLC): A proposal for quantitative immune-related pathologic response criteria (irPRC) (2018) (0)
- Radiation Immunodynamics as the Foundation of Immune-Guided Radiotherapy: Changes in Peripheral CD14+PD-L1+ Myeloid Cells over the Course of Chemoradiation and Association with Survival for New Diagnosis of Glioblastoma (2022) (0)
- Subset Diversity Tc17 CD8 T Cells: Functional Plasticity and (0)
- Conformation Dependent and Binds to the II-Restricted Tumor Antigen Is An Immunodominant MHC Class (2001) (0)
- 1058 - The Probiotic Potential of Non-Toxigenic Bacteroides Fragilis to Prevent Colitis and Tumorigenesis (2018) (0)
- Gene therapy for experimental brain tumors using a xenogenic cell line engineered to secrete hIL-2 (2007) (0)
- Abstract 6662: Studying immune responses against human endogenous retroviruses in immune checkpoint blockade-treated lung adenocarcinoma (2023) (0)
- Specific transgene expression in antigen presenting cells derived from lentivirally transduced hematopoietic stem/progenitor cells (2000) (0)
- Melanoma and immunotherapy bridge 2015 K1 Immunologic and metabolic consequences of PI3K/AKT/mTOR in melanoma (2016) (0)
- Distinct Myeloid Derived Suppressor Cell Populations Promote Tumor Aggression in Glioblastoma (2023) (0)
- Abstract PO008: The mouse colon modulates human microbes in transplantable murine tumor models after human fecal microbiota transfer (FMT) (2021) (0)
- Induction nivolumab or nivolumab/ipilimumab prior to concurrent chemoradiation plus nivolumab in patients with operable stage II/III esophageal/gastroesophageal junction cancer. (2018) (0)
- Abstract 3976: PD-1 blockade combined with TEGVAX (TLR agonists-enhanced GVAX) can induce regression of established palpable tumors. (2013) (0)
- 103 The myeloid immune signature of enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis (2015) (0)
- Abstract 2410: Supraphysiological androgens induce ferroptotic cell death in prostate cancer cells (2020) (0)
- 99 Solid tumor vaccines elicit distinct immune responses from host versus donor T cells in mixed chimeras created by non-myeloablative allogeneic stem cell transplantation (NST) (2003) (0)
- Lung tumor-infiltrating Treg have divergent transcriptional profiles and function linked to checkpoint blockade response (2022) (0)
- Abstract 2793: Mismatch repair proficient colorectal cancer and adaptive immunosuppression of endogenous anti-tumor immune response: Implications for immunotherapy (2019) (0)
- Timing of Vaccine Therapy May be Important in Prostate Cancer (2005) (0)
- Safety and immunologic correlates of allogeneic melanoma GVAX (MelGVAX), a genetically engineered whole-cell melanoma vaccine. (2014) (0)
- Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer (2023) (0)
- Bispecifics and CAR T cells that target intracellular cancer driver mutations (2021) (0)
- Contents Vol. 70 (2004) (2004) (0)
- IMMUNE CONTROL IN NEOPLASIA (1999) (0)
- 1990 AAAS Philip Hauge Abelson Prize. (1990) (0)
- Abstract LB-293: IL-2 diphtheria toxin fusion protein with anti-PD1: in mouse B16-F10 melanoma model (2018) (0)
- 1990 AAAS Philip Hauge Abelson Prize. (1990) (0)
- Dendritcellespecifikke costimulatory molecules (2001) (0)
- 17-Dependent AutoimmunityHT 17 Development andHSTAT 3 Signaling in T Cutting Edge : An In Vivo Requirement for (2007) (0)
- A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation (2021) (0)
- Tolerance Induction Phase During the Process of In Vivo T Cells Pass Through an Effector + CD 4 (2003) (0)
- Abstract 4041: Coupling neoantigen specific T cell clonotypes and their molecular phenotypes at the single cell level in resectable anti-PD-1 treated NSCLC (2019) (0)
- Participation of CD4 and CD8 Accessory Molecules in the Development and Selection of T Lymphocytes (1989) (0)
- Abstract LB-251: The checkpoint molecules LAG-3 and PD-1 synergize to maintain tolerance to tumors (2011) (0)
- Metabolism Links Bacteria l Biofilms and Colon Carcinogenesis Graphical Abstract Highlights (2015) (0)
- The Tyrosine Kinases pp561ck and pp59fyn are Activated in Thymocytes Undergoing Positive Selection (1993) (0)
- MA11.10 Peripheral T Cell Repertoire Evolution in Resectable NSCLC Treated with Neoadjuvant PD-1 Blockade (2019) (0)
- The intraductal injection of 5-fluorouracil for breast cancer: Preventive effect and immune response. (2012) (0)
- Transfer learning in a biomaterial fibrosis model identifies in vivo senescence heterogeneity and contributions to vascularization and matrix production across species and diverse pathologies. (2023) (0)
- Nippostrongylus Responses Induced by Costimulator B 7-DC Attenuates Strong Th 2 (2010) (0)
- Antigen-Specific CD4 T Cells Induce Distinct Transcriptional Profiles in Tumor Recognition and Self-Recognition (2009) (0)
- Enterotoxigenic Bacteroides fragilis colitis is regulated, in part, by CD4+ Tlymphocytes: P‐103. (2008) (0)
- IMPS-20COMBINATION THERAPY WITH ANTI-PD-1, ANTI-TIM-3, AND FOCAL RADIATION RESULTS IN REGRESSION OF MURINE GLIOMAS (2015) (0)
- Integrating Tissue Microenvironment with Scaffold Design to Promote Immune-Mediated Regeneration (2015) (0)
- Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 (Journal for Immuno Therapy of Cancer (2019) 7 (40) DOI: 10.1186/s40425-018-0492-x) (2019) (0)
- lentivirus-transduced engrafting human hematopoietic stem/progenitor cells Targeting transgene expression to antigen-presenting cells derived from (2013) (0)
- IL-2 AUGMENTS IMMTAC-DEPENDENT T CELL ACTIVATION AND TUMOUR CELL KILLING TARGETING A SHARED TP53 NEOANTIGEN WITH BISPECIFIC T CELL RETARGETING ANTIBODY (2020) (0)
- Abstract B42: Cyclic dinucleotides (CDNs) activated DC and NK cells in antitumor immunotherapy (2015) (0)
- 151 - Colonic Bacteria and the Tumor Immune Microenvironment of Colorectal Cancer Patients (2018) (0)
- The Immunodynamics of Myeloid-Derived Suppressor Cell and Monocyte Populations in the Peripheral Blood in Patients with Newly Diagnosed Glioblastoma Undergoing Adjuvant Temozolomide and Radiation Therapy (2019) (0)
- IMMU-27. SINGLE CELL RNA-SEQUENCING IDENTIFIES NOVEL BONE MARROW DERIVED MYELOID CELLS IN GLIOBLASTOMA ASSOCIATED WITH TUMOR AGGRESSION (2020) (0)
- 2845. Oral Antibiotic Use and Risk of Colorectal Cancer in the UK, 1989–2012: A Matched Case–Control Study (2019) (0)
- Activation et recrutement de cellules immunitaires induits par la listeria et methodes d'application associees (2006) (0)
- Non-toxigenic Bacteroides fragilis (NTBF) administration reduces bacteria-driven chronic colitis and tumor development independent of polysaccharide A (2018) (0)
- Abstract 2867: TH17 cells promote early pancreatic tumorigenesis. (2013) (0)
- Régulation des lymphocytes T (2004) (0)
- Neuritin promotes the expansion and persistence of regulatory T cells in vitro and in vivo. (P1051) (2013) (0)
- 266 Decoding the role of polyamine metabolism on anti-tumor immunity in head and neck cancer (2023) (0)
- A B16 melanoma cell line that exclusively metastasizes to the liver (2005) (0)
- Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer. (2023) (0)
- Cancer vaccines. (1993) (0)
- Reduced T-bet induction in proliferation- interferon-γ decoupled CD4+ T cells as a mechanism for propagated T cell tolerance (IRC4P.491) (2014) (0)
- Age-associated Senescent - T Cell Signaling Promotes Type 3 Immunity that Inhibits Regenerative Response (2022) (0)
- Abstract A088: Immune profiling of inflamed microsatellite stable colorectal cancer (2016) (0)
- Gene model correction for PVRIG in single cell and bulk sequencing data enables accurate detection and study of its functional relevance (2022) (0)
- Epigenetic therapy inhibits metastases by disrupting premetastatic niches (2020) (0)
- Abstract 2968: TH17 cells in early pancreatic tumorigenesis (2012) (0)
- Stimulated CD8 T Cells Subsets on Activated and Chronically Functionally Distinct LAG-3 and PD-1 (2009) (0)
- Stereotactic Radiation Combined with 41BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response an a Murine Glioma Model (2014) (0)
- RTHP-43 (LTBK-02). MULTI-TIME POINT EVALUATION OF PERIPHERAL BLOOD MYELOID-DERIVED SUPPRESSOR CELL AND LYMPHOCYTE POPULATIONS IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA RECEIVING ADJUVANT THERAPY (2019) (0)
- C-107 How checkpoint blockade alters the repertoire and function of tumor specific T-cells (2019) (0)
- OR.52. Phase I Evaluation of Therapeutic, E7-targeted DNA Vaccination in Women with HPV16+ High Grade Cervical Dysplasia (CIN2/3) (2008) (0)
- Patent Watch (2001) (0)
- 629 Targeting a shared TP53 neoantigen with bispecific T cell retargeting antibody (2020) (0)
- unologic Consequences of Signal Transducers and ivators of Transcription 3 Activation in Human R amous Cell Carcinoma (2010) (0)
- The microRNA-17 modulates Foxp3+ regulatory T cells activity by targeting Eos (P1073) (2013) (0)
- 1497TiP REACTION – a phase Ib pilot study of nivolumab or nivolumab in combination with relatlimab after targeted radiation in patients with advanced esophagogastric cancer (2020) (0)
- Author Correction: Targeting public neoantigens for cancer immunotherapy (2021) (0)
- Abstract LB095: Hybrid TCR-CAR design surpasses conventional CARs and patient-derived TCRs in targeting an ultra-low-density neoantigen (2023) (0)
- 836 Murine fecal microbiota transfer models colonize human microbes selectively and reveal transcriptional pathways associated with response to neoadjuvant checkpoint inhibitors (2021) (0)
- Cancer Immunology (2020) (0)
- Stat3 activation in enterotoxigenic Bacteroides fragilis induced intestinal inflammation: P‐098. (2008) (0)
- Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer (2013) (0)
- and Number of Cell Divisions Versus Priming Is Independent of the Rate T Cell Tolerance Induction + In Vivo CD4 (1999) (0)
- Infectious tolerance of LAG-3+ regulatory T cells with attenuated T-bet induction (IRC11P.433) (2015) (0)
- Abstract A32: Characterizing patterns of cytokine coexpression with immune checkpoint markers in CD4 and CD8 tumor-infiltrating lymphocytes (2020) (0)
- Dissecting the specificity of a TCR-mimic antibody targeting TP53 R175H mutation-derived neoantigen (2020) (0)
- Abstract 3843: Autologous resconstitution of human cancer and immune system in vivo (2017) (0)
- Caspase-1 from MDSC promote MyD88 dependent carcinogenesis that is T-cell independent (2016) (0)
- Costimulatory molecules of dendritic cells. (2001) (0)
- Modulation of expression of B7 homologs by human rhinovirus and double-stranded RNA in airway epithelial cells in vitro and in vivo (2004) (0)
- S1722 Enterotoxigenic Bacteroides Fragilis Induce E-Cadherin Shedding and TH17 Response in C57BL/6 Mice (2008) (0)
- This information is current as Cognate Antigen during Chronic Infection Persistence and Require Preservation of Acute Infection Are Associated with Viral Hepatitis C Virus-Specific T Cells during High-Programmed Death-1 Levels on (2013) (0)
- Cyclic dinucleotides (CDNs) anti-tumors response by activating DC and NK cell crosstalk (2014) (0)
- OA20.02 Neoantigen Targeting in NSCLC Patients with Complete Response to Anti-PD-1 Immunotherapy (2017) (0)
- Abstract 4292: Gene model correction for PVRIG and TIGIT in single cell sequencing data enables accurate detection and study of its functional relevance (2023) (0)
- Dendritzell-specific costimulatory molecules (2001) (0)
- Methods and compositions for gene therapy and strengthening the immune system. (1991) (0)
- MDSCs enhance tumor cell proliferation in a caspase-1 related inflammasome cytokines dependent way (2015) (0)
- 32: Role of STAT3 Signaling in GVHD and GVL (2008) (0)
- AutoimmunityResults in Tumor Rejection But Not Activation of Low Avidity CTL Specific for a Self (2017) (0)
- Role of human lymphocyte activation gene 3 in tumor infiltrating lymphocytes (101.12) (2010) (0)
- Abstract LB-456: The intraductal injection of 5-fluorouracil induces immune response to eradicate and prevent breast cancer (2011) (0)
- Adoptive transfer of Tc17 CD8 T cells leads to tumor inhibition and anti-tumor response (95.15) (2010) (0)
- CD137 Receptor by Dendritic Cells Cutting Edge: Expression of Functional (2002) (0)
- In vitro induction of non-responsiveness in cloned normal inducer T cells by antigen and purified Ia incorporated into planar membranes (1986) (0)
- Regulation par lymphocytes t (2004) (0)
- Age-related Immune-Stromal Networks Inhibit Response to Regenerative Immunotherapies (2021) (0)
This paper list is powered by the following services:
Other Resources About Drew Pardoll
What Schools Are Affiliated With Drew Pardoll?
Drew Pardoll is affiliated with the following schools:
